How BioDelivera launched BioDelivera on X
Programmable drug delivery that targets only diseased cells
What BioDelivera launched

Today we are launching @BioDelivera a programmable drug delivery platform that delivers therapies only to diseased cells enabling cures for every disease. 🎯🧪 Less than 3% of an injected therapy reaches diseased cells. The rest ends up in healthy organs. At @BioDelivera we want https://t.co/i0Ss2GDELF
Transcript
How LaunchVideo.com rated the launch
LaunchVideo.com rating
About the launch
BioDelivera is launching Guided Chimeric Vehicles, engineered nanoparticles designed to carry a therapy through the bloodstream, bind selected diseased cells, enter them, and release the cargo inside while limiting exposure to healthy organs. The San Francisco company, in Y Combinator's Fall 2026 batch, is building for oncology, gene therapy, and central nervous system disease, where most of an injected dose never reaches the intended cells. BioDelivera states that less than 3% of an injected therapy reaches diseased cells, with the rest accumulating in healthy organs, which it says forces lower doses and leaves patients sick from treatment. The vehicles self-assemble around the cargo and can carry small molecules, DNA, RNA, proteins, and gene editors, separately or together. Targeting can be set for cells in cancer, muscle, brain, and other hard-to-reach organs, including cells involved in age-related disease. The company reports efficacy in tumors, muscle, and brain, and says it is extending the same carrier to additional tissues. Founders Ikeda Trashi and Orikeda Trashi are twin sisters who completed PhDs at the University of Texas at Dallas. Ikeda is CEO and Orikeda is president. They started BioDelivera in 2025 on five years of drug delivery research, and they remain a two-person team.
Tags
Questions
Frequently asked questions
The BioDelivera launch post reached 16K views on X, with 289 likes, 36 reposts, 36 comments, 76 bookmarks.
BioDelivera launched on X on November 11, 2026 with the message "Programmable drug delivery that targets only diseased cells".
BioDelivera is launching Guided Chimeric Vehicles, engineered nanoparticles designed to carry a therapy through the bloodstream, bind selected diseased cells, enter them, and release the cargo inside.
LaunchVideo.com rated the BioDelivera launch 2.80 out of 5: hook 2/5, editing / creativity 3/5, copy 4/5, sentiment of launch 4/5, distribution strategy 1/5.







